7,956 Shares in IQVIA Holdings Inc. (NYSE:IQV) Purchased by Unique Wealth Strategies LLC

Unique Wealth Strategies LLC purchased a new position in IQVIA Holdings Inc. (NYSE:IQV) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 7,956 shares of the medical research company’s stock, valued at approximately $1,841,000. IQVIA makes up 1.2% of Unique Wealth Strategies LLC’s investment portfolio, making the stock its 18th biggest position.

Other institutional investors have also recently bought and sold shares of the company. AdvisorNet Financial Inc grew its stake in IQVIA by 327.6% during the 4th quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 95 shares in the last quarter. BKM Wealth Management LLC bought a new stake in shares of IQVIA in the 4th quarter valued at approximately $32,000. Activest Wealth Management bought a new stake in shares of IQVIA in the 4th quarter valued at approximately $35,000. CVA Family Office LLC bought a new stake in shares of IQVIA in the 4th quarter valued at approximately $43,000. Finally, CoreFirst Bank & Trust bought a new stake in shares of IQVIA in the 3rd quarter valued at approximately $44,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Activity

In other news, insider Eric Sherbet sold 1,000 shares of the firm’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $241.50, for a total value of $241,500.00. Following the completion of the sale, the insider now directly owns 20,836 shares in the company, valued at $5,031,894. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, insider Eric Sherbet sold 1,000 shares of IQVIA stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $241.50, for a total value of $241,500.00. Following the completion of the sale, the insider now directly owns 20,836 shares in the company, valued at $5,031,894. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Ari Bousbib sold 31,678 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the transaction, the insider now owns 796,752 shares in the company, valued at approximately $199,610,278.56. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 41,285 shares of company stock worth $10,331,003. 1.60% of the stock is owned by corporate insiders.

IQVIA Price Performance

IQVIA stock traded up $0.90 during mid-day trading on Friday, hitting $234.88. 697,640 shares of the company were exchanged, compared to its average volume of 761,918. The company has a quick ratio of 0.86, a current ratio of 0.86 and a debt-to-equity ratio of 2.12. The business has a fifty day moving average of $245.28 and a 200 day moving average of $223.02. IQVIA Holdings Inc. has a 1-year low of $167.42 and a 1-year high of $261.73. The company has a market capitalization of $42.63 billion, a PE ratio of 32.22, a price-to-earnings-growth ratio of 2.26 and a beta of 1.50.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.82 by $0.02. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. The firm had revenue of $3.87 billion during the quarter, compared to analyst estimates of $3.80 billion. During the same period in the prior year, the company posted $2.54 earnings per share. The business’s revenue for the quarter was up 3.5% compared to the same quarter last year. As a group, sell-side analysts expect that IQVIA Holdings Inc. will post 10.12 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. SVB Leerink assumed coverage on IQVIA in a research note on Monday, February 26th. They issued an “outperform” rating and a $290.00 price target for the company. Guggenheim lowered IQVIA from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. UBS Group boosted their target price on IQVIA from $240.00 to $300.00 and gave the stock a “buy” rating in a report on Thursday, February 15th. Evercore ISI boosted their target price on IQVIA from $255.00 to $265.00 and gave the stock a “market outperform” rating in a report on Thursday, February 15th. Finally, Robert W. Baird boosted their target price on IQVIA from $226.00 to $251.00 and gave the stock a “neutral” rating in a report on Thursday, February 15th. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and an average target price of $256.80.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.